Geoffrey M Duyk's Net Worth

$1.94 Million

Estimate Recalculated Nov 8, 2024 09:32PM EST

Who is Geoffrey M Duyk

Geoffrey M Duyk has an estimated net worth of $1.94 Million. This is based on reported shares across multiple companies, which include AMYRIS, INC., EXELIXIS INC, AERIE PHARMACEUTICALS INC, REPLIDYNE INC, and EPIRUS Biopharmaceuticals, Inc..

SEC CIK

Geoffrey M Duyk's CIK is 0001202090

Past Insider Trading and Trends

2003 was Geoffrey M Duyk's most active year for acquiring shares with 5 total transactions. Geoffrey M Duyk's most active month to acquire stocks was the month of July. 2017 was Geoffrey M Duyk's most active year for disposing of shares, totalling 10 transactions. Geoffrey M Duyk's most active month to dispose stocks was the month of January. 2017 saw Geoffrey M Duyk paying a total of $778,131.50 for 58,167 shares, this is the most they've acquired in one year. In 2017 Geoffrey M Duyk cashed out on 116,334 shares for a total of $2,717,739.84, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

AMYRIS, INC.

Investor
Updated May 07, 2024
Form 4
-100.00%
-40.55K
May 07, 2024
Disposition
May 07
Form 4
Feb 14, 2023
120.55K
Grant
Jan 03
Form 4
466.36%
80.00K
Aug 24, 2022
120.55K
Grant
Aug 22
Form 4
31.63%
9.74K
Jan 20, 2022
40.55K
Grant
Jan 18
Form 4
31.67%
7.41K
Aug 25, 2021
30.81K
Grant
Aug 23
Form 4
94.22%
13.03K
Aug 07, 2020
26.86K
Grant
Aug 05
Form 4
305.49%
13.03K
Oct 25, 2019
17.30K
Grant
Oct 23
Form 4
120.69%
35.00K
Nov 07, 2016
64.00K
Grant
Nov 03
Form 4
358.33%
43.00K
Jul 15, 2016
55.00K
Grant
Jul 13
Form 4
100.00%
9.00K
Aug 03, 2015
18.00K
Grant
Jul 30
Form 4
150.00%
9.00K
Aug 08, 2014
15.00K
Grant
Aug 06
Form 4
300.00%
9.00K
Aug 05, 2013
12.00K
Grant
Aug 01
Form 4
9.00K
Jul 23, 2012
9.00K
Grant
Jul 19
Form 4
20.00K
May 09, 2012
20.00K
Grant
May 07
Form 3
May 09, 2012
Form 4
20.00K
Mar 16, 2011
20.00K
Grant
Mar 15
Form 3
Sep 27, 2010
Showing 17 results

EXELIXIS INC

Pres R&D & CSO
Updated Nov 04, 2003
Form 4
-0.33%
-3.10K
$7.73
-$23.97K
Nov 04, 2003
941.36K
Sale
Nov 04
Form 4
Nov 03, 2003
850.00K
Acq/Dis
Oct 30
Form 4
-0.32%
-3.00K
$7.73
-$23.19K
Oct 31, 2003
944.46K
Sale
Oct 31
Form 4
-0.42%
-4.00K
$7.93
-$31.72K
Oct 14, 2003
947.46K
Sale
Oct 13
Form 4
-2.56%
-25.00K
$7.93
-$198.18K
Oct 14, 2003
951.46K
Sale
Sep 18 - Oct 09
Form 4
Jun 09, 2003
Form 4
Jun 03, 2003
Form 4
Jun 02, 2003
Form 4
May 30, 2003
Form 4
May 23, 2003
Form 4
May 16, 2003
Form 4
May 15, 2003
Form 4
May 15, 2003
Form 4
May 15, 2003
Showing 14 results

AERIE PHARMACEUTICALS INC

Investor
Updated Feb 16, 2017
Form 4
-89.63%
-58.17K
$30.05
-$1.94M
Feb 16, 2017
6.73K
Sale
Feb 14 - Feb 15
Form 4
688.24%
11.70K
Jun 09, 2016
13.40K
Grant
Jun 08
Form 4
11.70K
Apr 14, 2015
11.70K
Grant
Apr 10
Form 4
13.50K
Jun 13, 2014
13.50K
Grant
Jun 11
Form 3/A
Nov 25, 2013
Form 3
Oct 25, 2013
Showing 6 results

REPLIDYNE INC

Investor
Updated Feb 27, 2009
Form 4
Feb 27, 2009
Form 4
8.16K
May 12, 2008
8.16K
Grant
May 08
Form 4
16.31K
$10.00
$163.13K
Jun 30, 2006
16.31K
Grant
Jun 28
Form 3
Jun 27, 2006
Showing 4 results

EPIRUS Biopharmaceuticals, Inc.

Investor
Updated Jun 08, 2015
Form 4
9.00K
Jun 08, 2015
9.00K
Grant
Jun 05
Form 3
Jul 16, 2014
Showing 2 results